Common Patient Concerns about the Use of Glucagon-Like Peptide-1 Receptor Agonists in Diabetes Mellitus Management
The authors present a case of a 46-year-old woman with type 2 diabetes mellitus who has been on a treatment regimen involving diet, exercise, and metformin. After 2 years of treatment, she has a body mass index of 35 and a glycosylated hemoglobin level of 8.0%, and this level is increasing. Her physician recommends adding a glucagon-like peptide-1 (GLP-1) receptor agonist to her treatment regimen, prompting her to ask several questions. The authors present these questions along with proposed answers, highlighting the practical application of GLP-1 receptor agonists in the context of common patient concerns.
Journal of the American Osteopathic Association
1 Supplement 1
Freeman, Jeffrey S.; Gavin, James R.; and Spellman, Craig W., "Common Patient Concerns about the Use of Glucagon-Like Peptide-1 Receptor Agonists in Diabetes Mellitus Management" (2012). PCOM Scholarly Papers. 204.
This document is currently not available here.